Ono Pharmaceuticals' ROMVIMZA Approval Disrupts TGCT Treatment Market, Challenging TURALIO Ono Pharmaceuticals secures FDA approval for ROMVIMZA, a new treatment for tenosynovial giant cell tumors, competing against Daiichi Sankyo's TURALIO.

Ono Pharmaceuticals' ROMVIMZA Approval Disrupts TGCT Treatment Market, Challenging TURALIO #None #Tenosynovial #ROMVIMZA #TURALIO